PF-06651600

Unknown / undisclosed

Approvedregulatory verdict

Evidence outlook

Approved: severe alopecia areata in adults and adolescents 12 years and older (FDA)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also approved (1)
US
  • LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.
Product first approved 2023FDA label

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Vitiligo
NCT06072183 · Pfizer
2023-11-08 – 2027-07-30 · Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
What this study did
NCT06163326 · Pfizer
2024-01-19 – 2027-03-31 · Vitiligo
What this study did
NCT05583526 · Pfizer
2022-12-01 – 2026-02-05 · Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
What this study did
Other / comorbidity
NCT07029828 · Pfizer
2025-09-10 – 2030-06-26 · Severe Alopecia Areata
What this study did
NCT06873945 · Pfizer
2025-04-01 – 2028-03-19 · Alopecia Areata
What this study did
NCT07029711 · Pfizer
2025-07-31 – 2027-01-06 · Severe Alopecia Areata
What this study did
NCT04006457 · Pfizer
2019-07-18 – 2026-02-26 · Alopecia Areata
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT03732807 · Pfizer
2018-12-03 – 2021-06-24 · Alopecia Areata
What this study did
Phase 2 (16)
Vitiligo
NCT07152626 · Centre Hospitalier Universitaire de Nice
2026-03-12 – 2029-06-01 · Vitiligo
What this study did
NCT03715829 · Pfizer
2018-11-26 – 2021-02-05 · Active Non-segmental Vitiligo
What this study did
Other / comorbidity
NCT06373458 · Icahn School of Medicine at Mount Sinai
2024-08-13 – 2028-01 · Keloid
What this study did
NCT05743244 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2023-10-19 – 2027-10-30 · Diabetes Mellitus, Type 1
What this study did
NCT07219615 · Pfizer
2025-10-30 – 2027-04-23 · Chronic Spontaneous Urticaria
What this study did
NCT05636293 · Massachusetts General Hospital
2023-03-01 – 2026-04-09 · Celiac Disease
What this study did
NCT06795373 · Ahuva D Cices
2025-12-31 – 2026-03-31 · Chronic Spontaneous Urticaria, CSU
What this study did
NCT05879458 · Icahn School of Medicine at Mount Sinai
2023-05-17 – 2025-06-25 · CTCL, Mycosis Fungoides, Sezary Syndrome
What this study did
NCT05549934 · Emma Guttman
2022-12-15 – 2025-03-20 · Cicatricial Alopecia
What this study did
NCT04517864 · Pfizer
2020-09-15 – 2024-05-07 · Alopecia Areata
What this study did
NCT03395184 · Pfizer
2018-02-02 – 2023-10-19 · Crohn's Disease
What this study did
NCT02958865 · Pfizer
2017-02-03 – 2021-05-10 · Ulcerative Colitis
What this study did
NCT02974868 · Pfizer
2016-12-15 – 2019-05-15 · Alopecia Areata
What this study did
NCT02969044 · Pfizer
2016-12-20 – 2017-12-12 · Rheumatoid Arthritis
What this study did
Phase 1 (26)
Other / comorbidity
NCT06172348 · Pfizer
2024-02-01 – 2024-03-28 · Healthy Volunteers
What this study did
NCT05852340 · Pfizer
2023-05-09 – 2023-07-24 · Healthy Volunteers, Adult, Pharmacokinetics
What this study did
NCT05128058 · Pfizer
2021-10-22 – 2022-01-14 · Healthy
What this study did
NCT05097716 · Pfizer
2021-11-02 – 2022-01-10 · Healthy Volunteers
What this study did
NCT05040295 · Pfizer
2021-09-10 – 2021-11-19 · Healthy Participants
What this study did
NCT04390776 · Pfizer
2020-09-28 – 2021-07-19 · Healthy Participants
What this study did
NCT04655040 · Pfizer
2020-12-18 – 2021-03-05 · Healthy Participants
What this study did
NCT04634565 · Pfizer
2020-10-15 – 2020-11-19 · Healthy Participants
What this study did
NCT04266509 · Pfizer
2020-06-25 – 2020-09-10 · Healthy Volunteers
What this study did
NCT04355845 · Pfizer
2020-06-15 – 2020-08-10 · Healthy Volunteers
What this study did
NCT04037865 · Pfizer
2019-08-19 – 2020-03-31 · Renal Impairment
What this study did
NCT04016077 · Pfizer
2019-07-19 – 2020-03-05 · Hepatic Impairment, Healthy Participants
What this study did
NCT04092595 · Pfizer
2019-09-26 – 2020-01-15 · Healthy Volunteers
What this study did
NCT04018274 · Pfizer
2019-08-09 – 2019-10-16 · Healthy
What this study did
NCT04004663 · Pfizer
2019-07-15 – 2019-10-11 · Healthy Volunteers
What this study did
NCT03821493 · Pfizer
2019-02-21 – 2019-06-04 · Healthy Participants
What this study did
NCT03916393 · Pfizer
2019-04-15 – 2019-05-10 · Healthy Participants
What this study did
NCT03827668 · Pfizer
2019-02-07 – 2019-04-29 · Healthy
What this study did
NCT03762928 · Pfizer
2018-12-07 – 2019-02-21 · Healthy Subjects
What this study did
NCT03608241 · Pfizer
2018-09-21 – 2018-11-23 · Healthy Females
What this study did
NCT03232905 · Pfizer
2017-08-30 – 2017-11-22 · Healthy
What this study did
NCT02684760 · Pfizer
2016-02 – 2016-05 · Healthy
What this study did
NCT02309827 · Pfizer
2014-12 – 2016-04 · Healthy
What this study did

Competitive landscape

This drug's own stage for Vitiligo: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
PF-06651600: this drugPhase 3—JAK3/TECnot yet gradedNo reviewed efficacy summary in this indication
Ruxolitinib (Opzelura)ApprovedSmall moleculeJAK1/2not yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)Phase 3Small moleculeJAK, JAK1not yet gradedNo reviewed efficacy summary in this indication
GIA632Phase 2Monoclonal antibodyIL-15not yet gradedNo reviewed efficacy summary in this indication
Nomelcitinib (D-2570)Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ZasocitinibPhase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow PF-06651600 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 3Severe Alopecia AreataActive not recruiting
Est. primary completion 2026-12-02 · NCT07029711 · CT.gov ↗
What to watch
Phase 2Hidradenitis SuppurativaActive not recruiting
Est. primary completion 2026-12-08 · NCT07228390 · CT.gov ↗
What to watch
Phase 2Chronic Spontaneous UrticariaRecruiting
Est. primary completion 2026-12-25 · NCT07219615 · CT.gov ↗
What to watch
2027 (3)
March 2027 (1)
Phase 3VitiligoActive not recruiting
Est. primary completion 2027-03-31 · NCT06163326 · CT.gov ↗
What to watch
July 2027 (1)
Phase 3VitiligoActive not recruiting
Est. primary completion 2027-07-30 · NCT06072183 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2KeloidRecruiting
Est. primary completion 2027-08 · NCT06373458 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
Phase 3Alopecia AreataRecruiting
Est. primary completion 2028-03-19 · NCT06873945 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3Alopecia AreataRecruiting
Est. primary completion 2028-04-26 · NCT07733765 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
Phase 2VitiligoRecruiting
Est. primary completion 2029-01-01 · NCT07152626 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 3Severe Alopecia AreataRecruiting
Est. primary completion 2030-06-26 · NCT07029828 · CT.gov ↗
What to watch

See the full readout calendar ↗